Pearson Steven D, Whaley Christopher M, Emond Sarah K
Institute for Clinical & Economic Review, Boston, MA 02108, USA.
Brown University, Providence, RI 02912, USA.
J Comp Eff Res. 2025 Sep;14(9):e250083. doi: 10.57264/cer-2025-0083. Epub 2025 Jul 11.
Glucagon-like peptide 1 receptor agonists and glucagon-like peptide 1/gastric inhibitory polypeptide receptor agonists offer weight reduction and associated health benefits that, if sustained over time, have the potential to markedly improve population health. However, over 40% of US adults have obesity, translating into more than 100 million potential new users of obesity medications. Standing in the way of the major opportunity to improve health for these individuals is the massive and likely ongoing cost of treating such a large segment of the population, even though use of the treatments is estimated to be cost-effective over a lifetime. This paper analyzes the range of emerging market approaches and policy reforms that have the potential to help the broader US health system achieve affordable and equitable access to these medications, and the relative advantages, barriers and possible unintended consequences of each approach. We seek to present policymakers and industry leaders with insights and lessons learned from experts while offering a menu of options for the future that will help all stakeholders play an active part in an innovative future of pricing, coverage and payment for new obesity medications.
胰高血糖素样肽-1受体激动剂和胰高血糖素样肽-1/胃抑制多肽受体激动剂具有减轻体重及相关健康益处，若长期维持，有可能显著改善人群健康。然而，超过40%的美国成年人患有肥胖症，这意味着超过1亿潜在的肥胖症药物新用户。尽管据估计使用这些治疗方法在一生中具有成本效益，但治疗如此庞大的人群所需的巨大且可能持续的成本，成为改善这些人健康这一重大机遇的障碍。本文分析了一系列新兴市场方法和政策改革，这些方法有可能帮助更广泛的美国医疗系统以可承受且公平的方式获得这些药物，以及每种方法的相对优势、障碍和可能产生的意外后果。我们旨在向政策制定者和行业领导者提供从专家那里获得的见解和经验教训，同时提供一份未来的选择清单，这将有助于所有利益相关者积极参与肥胖症新药定价、覆盖范围和支付的创新未来。
